Eli Lilly's experimental obesity drug retatrutide showed up to 28.3% weight loss in a Phase 3 trial, setting a new benchmark for GLP-1 drugs. Analysts praise its efficacy but note tolerability concerns. The company also acquired Engage Biologics for genetic medicines and presented oncology data at ASCO. Despite a 7x five-year gain, recent stock performance is mixed, with a 1.4% year-to-date decline.